Cogentix Medical (CGNT) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Cognyte Announces Fourth Quarter and Fiscal Year Ended January 31, 2022 Results
April 5, 2022 7:00 AM EDTHERZLIYA, Israel--(BUSINESS WIRE)-- Cognyte Software Ltd. (NASDAQ: CGNT) (the Company, Cognyte, we, us and our), a global leader in investigative analytics software, today announced results for the three months and year ended January 31, 2022 (Q4 FYE22 and FYE22).
In the fourth quarter, revenue was $125 million, up about $7 million sequentially from the third quarter, but several million dollars below the midpoint of our guidance. Our results reflect continued supply chain issues, as well as a lower conversion of our pipeline than we expected at the time of our last earnings conference call. We are proactively addressing these issues, but... More
